NTLA
Intellia Therapeutics, Inc. Health Care In Vitro & In Vivo Diagnostic Substances Russell 3000
$12.47Close
$1.5BMarket cap
$8.04 – $17.8452-week range
Nov 5, 2026Next report
Highlights
Cautions
- Not in an uptrend 3 of 8 trend conditions
- Lagging the market RS 49 · weaker than 51% of stocks over 12 months
- Far from its high 30% below its 52-week high
- Results soon Nov 5, 2026, in 4 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
30%
1wk
up 11.2%
price change
1mo
up 3.4%
price change
12-month return
up 2%
market up 11% ·
its own down 16%
F-score
—
— Not assessed
Altman Z
-0.25
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
2.2×
price / book
Earnings yield
down 34.1%
EBIT / enterprise value
Cheaper than
24%
of the market · expensive
Revenue growth
up 17%
year on year
EPS growth
—
latest quarter
Sales growth
down 46%
latest quarter · -37 pts
ROE
down 53%
return on equity
Free cash margin
down 585%
-$395.9M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
6.6%
$0.83 a day · 2×ATR $10.82
RS
49 / 99
vs the universe
Trend
3 / 8
trend template
Relative volume
0.9×
vs 50-day average
Up/down volume
1.00
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Trend template · 3 of 8
- Price above the 150 and 200-day averages: fails
- 150-day average above the 200-day: fails
- 200-day average rising for a month: passes
- 50-day average above the 150 and 200-day: fails
- Price above the 50-day average: passes
- At least 30% above the 52-week low: passes
- Within 25% of the 52-week high: fails
- RS rank 70 or higher: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Shareholders diluted The share count rose 14.0% over the year, from 102m to 116m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 6, 2026
Results reaction
Aug 6, 2026+8% vs market2 sessions after results
Financials
- Gross
- Net -610%
- Free cash -585%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $58.0M | $33.1M | $52.1M | $36.3M | $57.9M | $67.7M |
| Gross margin | 100% | 100% | — | — | — | — |
| Operating income | -$136.6M | -$267.9M | -$458.2M | -$515.3M | -$534.3M | -$441.0M |
| Net income | -$134.2M | -$267.9M | -$474.2M | -$481.2M | -$519.0M | -$412.7M |
| Net margin | -231% | -810% | -910% | -1327% | -897% | -610% |
| Earnings per share | -$2.40 | -$3.78 | -$6.16 | -$5.42 | -$5.25 | -$3.81 |
| Free cash flow | -$53.5M | -$237.8M | -$346.8M | -$408.1M | -$354.7M | -$395.9M |
| Free cash margin | -92% | -719% | -665% | -1125% | -613% | -585% |
| Cash | $160.0M | $123.4M | $523.5M | $226.7M | $189.2M | $155.5M |
| Shareholders' equity | $527.1M | $1.0B | $1.2B | $1.1B | $872.0M | $671.4M |
| Shares outstanding | 66.23m | 74.49m | 87.10m | 93m | 102.03m | 116.32m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 6, 2026 | Quarterly ↗ | Jun 30, 2026 | 37d |
| May 11, 2026 | Quarterly ↗ | Mar 31, 2026 | 41d |
| Feb 26, 2026 | Annual ↗ | Dec 31, 2025 | 57d |
| Nov 6, 2025 | Quarterly ↗ | Sep 30, 2025 | 37d |
| Aug 7, 2025 | Quarterly ↗ | Jun 30, 2025 | 38d |
| May 8, 2025 | Quarterly ↗ | Mar 31, 2025 | 38d |
| Feb 27, 2025 | Annual ↗ | Dec 31, 2024 | 58d |
| Nov 7, 2024 | Quarterly ↗ | Sep 30, 2024 | 38d |
| Aug 8, 2024 | Quarterly ↗ | Jun 30, 2024 | 39d |
| May 9, 2024 | Quarterly ↗ | Mar 31, 2024 | 39d |
| Feb 22, 2024 | Annual ↗ | Dec 31, 2023 | 53d |
| Nov 9, 2023 | Quarterly ↗ | Sep 30, 2023 | 40d |
Current reports
| Filed | Disclosed |
|---|---|
| Sep 8, 2026 | Regulation FD · Other events ↗ |
| Sep 4, 2026 | Material agreement · New obligation · Regulation FD ↗ |
| Aug 6, 2026 | Results ↗ |
| Jun 15, 2026 | Regulation FD · Other events ↗ |
| Jun 10, 2026 | Shareholder vote ↗ |
| May 11, 2026 | Results ↗ |
| Apr 30, 2026 | Material agreement · Results ↗ |
| Apr 27, 2026 | Regulation FD · Other events ↗ |
| Apr 10, 2026 | Charter or bylaws ↗ |
| Mar 2, 2026 | Material agreement · Regulation FD · Other events ↗ |
| Feb 26, 2026 | Results ↗ |
| Jan 27, 2026 | Regulation FD · Other events ↗ |